Janux Therapeutics, Inc.
No enriched coverage for $JANX in the last 7 days.
No SEC Form 4 filings for $JANX in the last 30 days.
This article discusses the potential upside for Janux Therapeutics (JANX) as perceived by Wall Street analysts, who estimate a significant increase of 180.44%. It suggests that the stock could see substantial growth based on current analyst projections.
Janux Therapeutics reported a net loss of $24.4 million for Q1 2026, consistent with the prior year, but maintained a robust cash position of $956.4 million. The company received a $35 million milestone payment from Bristol Myers Squibb and continues to advance its clinical pipeline, including JANX007, JANX014, and JANX011, while discontinuing JANX008 to reallocate resources.
Several insiders at Janux Therapeutics (NASDAQ:JANX) have sold shares over the past year, which could be a warning sign for investors. Although insider selling can have various explanations, significant sales from multiple insiders warrant further investigation. While the insiders still hold a fair chunk of the company, the sales and two existing warning signs suggest caution for potential investors.
